Restarting Anticoagulation in Certain VTE Cases Cost-Effective

This article originally appeared here.
Share this content:
Restarting Anticoagulation in Certain VTE Cases Cost-Effective
Restarting Anticoagulation in Certain VTE Cases Cost-Effective

WEDNESDAY, May 31, 2017 (HealthDay News) -- Restarting anticoagulation therapy may be cost-effective for patients with a predicted one-year venous thromboembolism (VTE) risk of 17.5 percent or higher, according to a study published online May 18 in the Journal of Thrombosis and Haemostasis.

Mark Monahan, from the University of Birmingham in the United Kingdom, and colleagues examined the long-term cost-effectiveness of using a decision rule for restarting anticoagulation therapy versus no extension of therapy based on a patient's risk of further unprovoked VTE. A Markov patient-level simulation model was developed, which adopted a lifetime time horizon from the perspective of the U.K. National Health Service/Personal Social Services.

The researchers found that if decision makers are willing to pay up to £20,000 per quality-adjusted life-year gained, treating patients with a predicted one-year VTE risk of 17.5 percent or higher may be cost-effective. The model was highly sensitive to overall parameter uncertainty, warranting caution in choosing the optimal decision rule on the grounds of cost-effectiveness. Anticoagulation therapy disutility and mortality risks were highly influential for driving the results in univariate sensitivity analyses.

"This represents the first economic model to consider the use of a decision rule for restarting therapy for unprovoked VTE patients," the authors write. "Better data are required to predict long-term bleeding risks on therapy in this patient group."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ground Beef Recalled After E. Coli Outbreak

Ground Beef Recalled After <i>E. Coli</i> Outbreak

Beef was produced and packaged at Cargill Meat Solutions in Fort Morgan, Colo.

Prevalence of Alzheimer's, Related Dementia Set to Double

Prevalence of Alzheimer's, Related Dementia Set to Double

Alzheimer's disease and related dementias burden is expected to increase to 3.3 percent in 2060

Long-Term Outcomes of Breast Implants Explored

Long-Term Outcomes of Breast Implants Explored

Higher rates of Sjogren syndrome, scleroderma, RA, stillbirth, melanoma for silicone implants

is free, fast, and customized just for you!




Already a member?

Sign In Now »